CLXPF - Cybin selects anxiety disorder indications for psychedelic molecule CYB004

Cybin (CLXPF) announces that it has selected social anxiety disorder (“SAD”) and generalized anxiety disorder (“GAD”) as the initial target indications for its proprietary psychedelic molecule CYB004.Various studies reviewing the improvements in anxiety with psychedelic treatments showed a significant response to therapy and were relatively well-tolerated.In these studies, patients benefited from a faster onset of action with less addictive effects, the company said."The decision to pursue anxiety disorders indications for CYB004 follows months of thoughtful, in-depth work by the Cybin development team," CEO Doug Drysdale said.Current global estimates for GAD market size are about $2.99B and projected to grow to $4.5B by 2027, while the current SAD US market is estimated at $165M with global estimates of $1.15B as of 2021.

For further details see:

Cybin selects anxiety disorder indications for psychedelic molecule CYB004